CA2101337A1 - Methode de production de fragments f(ab') d'immunoglobulines - Google Patents

Methode de production de fragments f(ab') d'immunoglobulines

Info

Publication number: CA2101337A1
Authority: CA; Canada
Prior art keywords: fragments; fab; medium; immunoglobulin; accordance
Prior art date: 1991-02-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2101337

Other languages

English (en)

Inventor

Stephan D. Glenn

Paulette E. Smariga

Edward O'connell

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Coulter Corp

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-02-01

Filing date

1992-01-29

Publication date

1992-08-02

1992-01-29 Application filed by Individual filed Critical Individual

1992-08-02 Publication of CA2101337A1 publication Critical patent/CA2101337A1/fr

Status Abandoned legal-status Critical Current

Links

239000012634 fragment Substances 0.000 title claims abstract description 121
108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 100
102000018358 immunoglobulin Human genes 0.000 title claims abstract description 100
229940072221 immunoglobulins Drugs 0.000 title claims abstract description 29
238000000034 method Methods 0.000 title claims description 53
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 72
239000003636 conditioned culture medium Substances 0.000 claims abstract description 34
210000004408 hybridoma Anatomy 0.000 claims abstract description 30
238000004519 manufacturing process Methods 0.000 claims abstract description 15
239000003638 chemical reducing agent Substances 0.000 claims abstract description 7
239000002609 medium Substances 0.000 claims description 36
230000029087 digestion Effects 0.000 claims description 27
238000006243 chemical reaction Methods 0.000 claims description 26
210000002966 serum Anatomy 0.000 claims description 21
230000001143 conditioned effect Effects 0.000 claims description 19
241000283707 Capra Species 0.000 claims description 16
239000002253 acid Substances 0.000 claims description 16
230000002829 reductive effect Effects 0.000 claims description 14
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 12
239000001963 growth medium Substances 0.000 claims description 11
238000011534 incubation Methods 0.000 claims description 11
102000004169 proteins and genes Human genes 0.000 claims description 11
108090000623 proteins and genes Proteins 0.000 claims description 11
238000006722 reduction reaction Methods 0.000 claims description 9
239000000126 substance Substances 0.000 claims description 9
238000003776 cleavage reaction Methods 0.000 claims description 8
230000007017 scission Effects 0.000 claims description 8
241000282414 Homo sapiens Species 0.000 claims description 7
229910000160 potassium phosphate Inorganic materials 0.000 claims description 6
235000011009 potassium phosphates Nutrition 0.000 claims description 6
230000001419 dependent effect Effects 0.000 claims description 4
238000011026 diafiltration Methods 0.000 claims description 4
239000012528 membrane Substances 0.000 claims description 4
241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
241000700159 Rattus Species 0.000 claims description 3
230000008859 change Effects 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
239000003104 tissue culture media Substances 0.000 claims 4
239000010755 BS 2869 Class G Substances 0.000 claims 2
241000699666 Mus <mouse, genus> Species 0.000 claims 2
210000003719 b-lymphocyte Anatomy 0.000 claims 2
238000000184 acid digestion Methods 0.000 claims 1
239000007795 chemical reaction product Substances 0.000 claims 1
239000013627 low molecular weight specie Substances 0.000 claims 1
230000003472 neutralizing effect Effects 0.000 claims 1
102000035195 Peptidases Human genes 0.000 abstract description 41
108091005804 Peptidases Proteins 0.000 abstract description 41
230000016784 immunoglobulin production Effects 0.000 abstract description 2
239000004365 Protease Substances 0.000 description 42
235000019419 proteases Nutrition 0.000 description 31
230000000694 effects Effects 0.000 description 29
239000000499 gel Substances 0.000 description 23
239000000047 product Substances 0.000 description 17
239000002158 endotoxin Substances 0.000 description 13
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 12
235000018102 proteins Nutrition 0.000 description 10
239000000243 solution Substances 0.000 description 10
102000003908 Cathepsin D Human genes 0.000 description 9
108090000258 Cathepsin D Proteins 0.000 description 9
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 8
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 8
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 8
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 8
102000057297 Pepsin A Human genes 0.000 description 8
108090000284 Pepsin A Proteins 0.000 description 8
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
238000004128 high performance liquid chromatography Methods 0.000 description 8
238000011282 treatment Methods 0.000 description 8
229940111202 pepsin Drugs 0.000 description 7
239000006228 supernatant Substances 0.000 description 7
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 6
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
239000000427 antigen Substances 0.000 description 6
102000036639 antigens Human genes 0.000 description 6
108091007433 antigens Proteins 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
108010091212 pepstatin Proteins 0.000 description 6
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 6
238000000746 purification Methods 0.000 description 6
239000000758 substrate Substances 0.000 description 6
239000002753 trypsin inhibitor Substances 0.000 description 6
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 5
102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
239000007983 Tris buffer Substances 0.000 description 5
229940122618 Trypsin inhibitor Drugs 0.000 description 5
101710162629 Trypsin inhibitor Proteins 0.000 description 5
239000000872 buffer Substances 0.000 description 5
238000004587 chromatography analysis Methods 0.000 description 5
239000000356 contaminant Substances 0.000 description 5
239000012530 fluid Substances 0.000 description 5
229950000964 pepstatin Drugs 0.000 description 5
229940093916 potassium phosphate Drugs 0.000 description 5
239000007858 starting material Substances 0.000 description 5
FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 4
102000005600 Cathepsins Human genes 0.000 description 4
108010084457 Cathepsins Proteins 0.000 description 4
108090000526 Papain Proteins 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000027455 binding Effects 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 4
239000012467 final product Substances 0.000 description 4
239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
230000009467 reduction Effects 0.000 description 4
235000017550 sodium carbonate Nutrition 0.000 description 4
229940001593 sodium carbonate Drugs 0.000 description 4
229910000029 sodium carbonate Inorganic materials 0.000 description 4
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
229920000936 Agarose Polymers 0.000 description 3
102000004411 Antithrombin III Human genes 0.000 description 3
108090000935 Antithrombin III Proteins 0.000 description 3
GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
101710097834 Thiol protease Proteins 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
229960005348 antithrombin iii Drugs 0.000 description 3
150000001540 azides Chemical class 0.000 description 3
238000011109 contamination Methods 0.000 description 3
229960002433 cysteine Drugs 0.000 description 3
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
235000018417 cysteine Nutrition 0.000 description 3
230000007423 decrease Effects 0.000 description 3
238000000760 immunoelectrophoresis Methods 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
230000037230 mobility Effects 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
229940055729 papain Drugs 0.000 description 3
235000019834 papain Nutrition 0.000 description 3
238000005464 sample preparation method Methods 0.000 description 3
241000894007 species Species 0.000 description 3
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
229960001322 trypsin Drugs 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
108091005508 Acid proteases Proteins 0.000 description 2
206010003445 Ascites Diseases 0.000 description 2
102000004506 Blood Proteins Human genes 0.000 description 2
108010017384 Blood Proteins Proteins 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
108090001069 Chymopapain Proteins 0.000 description 2
102000006395 Globulins Human genes 0.000 description 2
108010044091 Globulins Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
101000985214 Mus musculus 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 2
108010058846 Ovalbumin Proteins 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
108010065081 Phosphorylase b Proteins 0.000 description 2
ISWQCIVKKSOKNN-UHFFFAOYSA-L Tiron Chemical compound [Na+].[Na+].OC1=CC(S([O-])(=O)=O)=CC(S([O-])(=O)=O)=C1O ISWQCIVKKSOKNN-UHFFFAOYSA-L 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
238000003556 assay Methods 0.000 description 2
229960002319 barbital Drugs 0.000 description 2
102000005936 beta-Galactosidase Human genes 0.000 description 2
108010005774 beta-Galactosidase Proteins 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000006143 cell culture medium Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229960002976 chymopapain Drugs 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
238000012258 culturing Methods 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
238000001641 gel filtration chromatography Methods 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000002955 isolation Methods 0.000 description 2
230000002132 lysosomal effect Effects 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
229940092253 ovalbumin Drugs 0.000 description 2
230000020477 pH reduction Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
238000012421 spiking Methods 0.000 description 2
229940033663 thimerosal Drugs 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
JVIPLYCGEZUBIO-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1 JVIPLYCGEZUBIO-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
208000035404 Autolysis Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
102000003846 Carbonic anhydrases Human genes 0.000 description 1
108090000209 Carbonic anhydrases Proteins 0.000 description 1
206010057248 Cell death Diseases 0.000 description 1
101000952982 Conus striatus Conopressin-S Proteins 0.000 description 1
229920001425 Diethylaminoethyl cellulose Polymers 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
108090000371 Esterases Proteins 0.000 description 1
102000009109 Fc receptors Human genes 0.000 description 1
108010087819 Fc receptors Proteins 0.000 description 1
108090000270 Ficain Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
102100023915 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
238000011050 LAL assay Methods 0.000 description 1
108010006035 Metalloproteases Proteins 0.000 description 1
102000005741 Metalloproteases Human genes 0.000 description 1
108090000143 Mouse Proteins Proteins 0.000 description 1
102000003505 Myosin Human genes 0.000 description 1
108060008487 Myosin Proteins 0.000 description 1
241000609499 Palicourea Species 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
241000208474 Protea Species 0.000 description 1
101100156763 Schizosaccharomyces pombe (strain 972 / ATCC 24843) wos2 gene Proteins 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
108010022999 Serine Proteases Proteins 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
108010023197 Streptokinase Proteins 0.000 description 1
MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000011149 active material Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
239000013584 assay control Substances 0.000 description 1
239000003637 basic solution Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
101150061829 bre-3 gene Proteins 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
244000309466 calf Species 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
230000006862 enzymatic digestion Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
235000019836 ficin Nutrition 0.000 description 1
POTUGHMKJGOKRI-UHFFFAOYSA-N ficin Chemical compound FI=CI=N POTUGHMKJGOKRI-UHFFFAOYSA-N 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
229940098197 human immunoglobulin g Drugs 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
229940027941 immunoglobulin g Drugs 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000003993 interaction Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
IZXGZAJMDLJLMF-UHFFFAOYSA-N methylaminomethanol Chemical compound CNCO IZXGZAJMDLJLMF-UHFFFAOYSA-N 0.000 description 1
239000000203 mixture Substances 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
VBEGHXKAFSLLGE-UHFFFAOYSA-N n-phenylnitramide Chemical compound [O-][N+](=O)NC1=CC=CC=C1 VBEGHXKAFSLLGE-UHFFFAOYSA-N 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
210000004493 neutrocyte Anatomy 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000003359 percent control normalization Methods 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
238000000275 quality assurance Methods 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
238000011363 radioimmunotherapy Methods 0.000 description 1
230000001869 rapid Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000004044 response Effects 0.000 description 1
230000028043 self proteolysis Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000003643 water by type Substances 0.000 description 1
JLYXXMFPNIAWKQ-UHFFFAOYSA-N γ Benzene hexachloride Chemical compound ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl JLYXXMFPNIAWKQ-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

CA 2101337 1991-02-01 1992-01-29 Methode de production de fragments f(ab') d'immunoglobulines Abandoned CA2101337A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US64974991A	1991-02-01	1991-02-01
US649,749		1991-02-01

Publications (1)

Publication Number	Publication Date
CA2101337A1 true CA2101337A1 (fr)	1992-08-02

Family

ID=24606069

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2101337 Abandoned CA2101337A1 (fr)	1991-02-01	1992-01-29	Methode de production de fragments f(ab') d'immunoglobulines

Country Status (5)

Country	Link
EP (1)	EP0569525A1 (fr)
JP (1)	JPH06505731A (fr)
AU (1)	AU1331892A (fr)
CA (1)	CA2101337A1 (fr)
WO (1)	WO1992013876A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2606142B1 (fr) *	2010-08-20	2018-02-28	Boehringer Ingelheim International GmbH	Procédé d'inactivation de protéases dans un fluide obtenu à partir d'une culture de cellules par modification du ph
WO2014031662A2 (fr)	2012-08-21	2014-02-27	Ortho-Clinical Diagnostics, Inc	Anticorps dirigés contre l'olanzapine et leur utilisation
CA2882595C (fr) *	2012-08-21	2019-06-04	Ortho-Clinical Diagnostics, Inc.	Anticorps diriges contre des haptenes d'olanzapine et leur utilisation
US10376582B2 (en)	2013-10-16	2019-08-13	Outlook Therapeutics, Inc.	Buffer formulations for enhanced antibody stability
WO2016118707A1 (fr)	2015-01-21	2016-07-28	Oncobiologics, Inc.	Modulation de variants de charge dans une composition d'anticorps monoclonaux
EP3400242A1 (fr) *	2016-01-06	2018-11-14	Oncobiologics, Inc.	Réduction des espèces de masse moléculaire élevée, des espèces de charge acide, et des fragments dans une composition d'anticorps monoclonaux
AU2017213775A1 (en)	2016-02-03	2018-08-16	Outlook Therapeutics, Inc.	Buffer formulations for enhanced antibody stability

1992
- 1992-01-29 CA CA 2101337 patent/CA2101337A1/fr not_active Abandoned
- 1992-01-29 EP EP19920906060 patent/EP0569525A1/fr not_active Withdrawn
- 1992-01-29 AU AU13318/92A patent/AU1331892A/en not_active Abandoned
- 1992-01-29 JP JP4506284A patent/JPH06505731A/ja active Pending
- 1992-01-29 WO PCT/US1992/000768 patent/WO1992013876A1/fr not_active Ceased

Also Published As

Publication number	Publication date
WO1992013876A1 (fr)	1992-08-20
AU1331892A (en)	1992-09-07
EP0569525A1 (fr)	1993-11-18
JPH06505731A (ja)	1994-06-30

Publication	Publication Date	Title
EP0419574B1 (fr)	1995-11-08	Anticorps monoclonaux contre la region a chaine legere du facteur humain xii et procedes de preparation et d'utilisation de ces anticorps
Ploug et al.	1994	Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor
Mortensen et al.	1984	Purification and characterization of an immunoglobulin A1 protease from Bacteroides melaninogenicus
Girma et al.	1986	Limited proteolysis of human von Willebrand factor by Staphylococcus aureus V-8 protease: isolation and partial characterization of a platelet-binding domain
Solomon et al.	1976	Bence-Jones proteins and light chains of immunoglobulins
Clark et al.	1986	Antibodies prepared to Bacillus cereus phospholipase C crossreact with a phosphatidylcholine preferring phosoholipase C in mammalian cells
Sekiguchi et al.	1985	Differences in domain structure between human fibronectins isolated from plasma and from culture supernatants of normal and transformed fibroblasts. Studies with domain-specific antibodies.
Schielen et al.	1989	The sequence A alpha-(148-160) in fibrin, but not in fibrinogen, is accessible to monoclonal antibodies.
Matsuura et al.	1994	Amidase activity of human Bence Jones proteins
CA1341506C (fr)	2006-06-06	Polypeptides coagulants analogues au facteur viii ainsi que des anticorps monoclonaux que leur sont specifiques
Masson	1989	A naturally occurring molecular form of human plasma cholinesterase is an albumin conjugate
Hubbard et al.	1989	Vitamin K-dependent carboxylase: affinity purification from bovine liver by using a synthetic propeptide containing the gamma-carboxylation recognition site.
PL166810B1 (pl)	1995-06-30	Sposób oczyszczania chymopapalny PL PL PL PL PL PL PL
CA2006684C (fr)	1996-12-17	Anticorps monoclonaux contre la proteine c
CA2101337A1 (fr)	1992-08-02	Methode de production de fragments f(ab') d'immunoglobulines
Ishidoh et al.	1998	Multiple Processing of Procathepsin L to Cathepsin Lin Vivo
AU650419B2 (en)	1994-06-23	Polyvalent metal ion-containing antibody combining site catalysts
Haeffner-Cavaillon et al.	1979	Studies on the Fcγ Receptor of the Murine Macrophage-Like Cell Line P388D1: II. Binding of Human IgG Subclass Proteins and Their Proteolytic Fragments
Laurell et al.	1985	Characterization of monoclonal antibodies against human protein C specific for the calcium ion‐induced conformation or for the activation peptide region
EP0139447B1 (fr)	1992-12-30	Procéde pour la préparation du Zymogène d'urokinase
Sugo et al.	1990	Anti-human factor IX monoclonal antibodies specific for calcium ion-induced conformations
Solomon et al.	1976	Bence Jones Proteins and Light Chains of Immunoglobulins: XIII. Effect of Elastase-like and Chymotrypsin-like Neutral Proteases Derived from Human Granulocytes on Bence Jones Proteins
US4683221A (en)	1987-07-28	Lymphocyte-activating polypeptides
US5688919A (en)	1997-11-18	Process for the purification of factor XIII, monoclonal antibodies against factor XIIIA, the preparation and use thereof
FI80293B (fi)	1990-01-31	Foerfarande foer framstaellning av intakt rekombinent humanimmuninterferon.

Legal Events

Date	Code	Title	Description
1995-07-29	FZDE	Dead